Pneumococcal conjugate second or third-dose vaccines (PCVc) in Upper-middle income (World Bank)
Upper-middle income (World Bank): Pneumococcal conjugate second or third-dose vaccines (PCVc) was 49.0% in 2025. ▲ Rising
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Upper-middle income (World Bank), 2008–2025
Source: World Health Organization, Global Health Observatory.
Analysis
Upper-middle income (World Bank) recorded 49.0% for pneumococcal conjugate second or third-dose vaccines (pcvc) in 2025. That is the highest value across all 18 years on record.
Compared with earlier readings it is up 4.3% on the previous year and up 104.2% over ten years.
Over the whole period, pneumococcal conjugate second or third-dose vaccines (pcvc) in Upper-middle income (World Bank) peaked at 49.0% in 2025 and was at its lowest, 1.0%, in 2008.
The long-run direction has been consistently rising across the 18 years of available data.
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Upper-middle income (World Bank), year by year
| Year | Value | Change |
|---|---|---|
| 2008 | 1.0% | — |
| 2009 | 5.0% | +400.0% |
| 2010 | 12.0% | +140.0% |
| 2011 | 17.0% | +41.7% |
| 2012 | 19.0% | +11.8% |
| 2013 | 21.0% | +10.5% |
| 2014 | 24.0% | +14.3% |
| 2015 | 24.0% | +0.0% |
| 2016 | 26.0% | +8.3% |
| 2017 | 27.0% | +3.8% |
| 2018 | 29.0% | +7.4% |
| 2019 | 30.0% | +3.4% |
| 2020 | 31.0% | +3.3% |
| 2021 | 31.0% | +0.0% |
| 2022 | 34.0% | +9.7% |
| 2023 | 41.0% | +20.6% |
| 2024 | 47.0% | +14.6% |
| 2025 | 49.0% | +4.3% |
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 3.0% | 1.0% | 5.0% | 2 |
| 2010s | 22.9% | 12.0% | 30.0% | 10 |
| 2020s | 38.8% | 31.0% | 49.0% | 6 |
Countries ranked near Upper-middle income (World Bank)
- 11 Turkmenistan 98.0% compare
- 11 El Salvador 98.0% compare
- 11 Portugal 98.0% compare
- 11 Costa Rica 98.0% compare
- 11 Saudi Arabia 98.0% compare
- 11 Mauritius 98.0% compare
More health data for Upper-middle income (World Bank)
- Pertussis - number of reported cases 63,803 (2025)
- Diphtheria - number of reported cases 1,556 (2025)
- Measles - number of reported cases 91,627 (2025)
- Total tetanus - number of reported cases 5,773 (2025)
- Neonatal tetanus - number of reported cases 212 (2025)
- Infant mortality rate (probability of dying between birth and age 1) 10.9 (2024)
- Number of neonatal deaths 196,632 (2024)
- Thinness among children and adolescents, BMI-for-age < -2 standard 4.0% (2024)
- Under-five mortality rate 13.12 (2024)
- Neonatal mortality rate 6.78 (2024)
Frequently asked questions
- What is pneumococcal conjugate second or third-dose vaccines (pcvc) in Upper-middle income (World Bank)?
- Pneumococcal conjugate second or third-dose vaccines (pcvc) in Upper-middle income (World Bank) was 49.0% in 2025, according to World Health Organization, Global Health Observatory.
- What is the highest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Upper-middle income (World Bank)?
- The highest recorded value was 49.0% in 2025.
- What is the lowest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Upper-middle income (World Bank)?
- The lowest recorded value was 1.0% in 2008.
- How does Upper-middle income (World Bank) rank for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Upper-middle income (World Bank) ranks 10th out of 11 groups with data for 2025.
- Is pneumococcal conjugate second or third-dose vaccines (pcvc) rising or falling in Upper-middle income (World Bank)?
- Over the last ten years it is up 104.2%. The long-run trend across the full record is rising.
- Where does this Upper-middle income (World Bank) data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 18 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).